Biomarkeri u multiploj sklerozi

master's thesis

• Title (english): Biomarkers of multiple sclerosis
• Author: Leonarda Grošić
• Mentor: Sandra Šupraha-Goreta (mentor)
• Committee member: Sandra Šupraha-Goreta (predsjednik povjerenstva)
• Committee member: Lidija Bach-Rojecky (član povjerenstva)
• Committee member: Anita Somborac Bačura (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of biochemistry and molecular biology); Zagreb
• Defense date and country: 2022-03-11, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Medical Biochemistry

Abstract

Multipla skleroza (engl. multiple sclerosis, MS) je kronična upalna demijelinizacijska bolest
središnjeg živčanog sustava (SŽS). Uzrok MS je nepoznat, no smatra se da je MS multikomponentna
bolest do koje dolazi prisutnošću genske predispozicije i autoimunosnim odgovorom koji je potaknut
infekcijom. Razvoj novih metoda i biljega omogućuje uvid u dosad nepoznatu patogenezu bolesti.
Standardi za dijagnostiku MS su oligoklonalne vrpce, IgG indeks i MRZ reakcija u kliničkoj praksi.
Prognostički biomarkeri za MS mogu pružiti informacije o tijeku aktivnosti bolesti i ukazati na
konverziju u drugi oblik MS (detekcija oligoklonalnih vrpca IgG u likvoru, detekcija oligoklonalnih
vrpca IgM u likvoru, CHI3L1, NF, N-CAM, MMP). Biomarkeri terapije (CXCL13, NFL, vitamin
D, BDNF) u postupku su istraživanja i implementacije. U istraživanjima je pokazana mogućnost
primjene novih biomarkera, cfDNA i miRNA, prilikom dijagnoze, praćenja tijeka bolesti i terapije
MS koji bi kao takvi bili neinvazivni biomarkeri. Razvoj metode sekvenciranja nove generacije,
omogućio je otkrivanje novih čimbenika uključenih u patogenezi MS, potencijalnih biomarkera gena
i novih meta za razvoj lijekova.

Abstract (english)

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous
system (CNS). The cause of MS is unknown, but MS is thought to be a multicomponent disease
caused by the presence of a genetic predisposition and an autoimmune response triggered by
infection. The development of new methods and markers provides insight into the unknown
pathogenesis of the disease. Standards for the diagnosis of MS are oligoclonal bands, IgG index
and MRZ reactions in clinical practice. Prognostic biomarkers for MS can provide information
on the course of disease activity and indicate conversion to another form of MS (detection of
oligoclonal IgG bands in cerebrospinal fluid, detection of oligoclonal bands IgM in cerebrospinal
fluid, CHI3L1, NF, N-CAM, MMP). Biomarkers of therapy (CXCL13, NFL, vitamin D, BDNF)
are in the process of research and implementation. Research has shown the possibility of using
new biomarkers, cfDNA and miRNA, in the diagnosis, monitoring of the course of the disease
and therapy of MS, which as such would be non-invasive biomarkers. The development of a new
generation sequencing method has made it possible to discover new factors involved in the
pathogenesis of MS, potential gene biomarkers and new targets for drug development.

• Keywords: multipla skleroza; biomarkeri; dijagnostika; cfDNA; miRNA; sekvenciranje nove generacije
• Keywords (english): multiple sclerosis; biomarkers; diagnosis; cfDNA; miRNA; next generation sequencing
• Language: croatian
• URN:NBN: urn:nbn:hr:163:106817
• Study programme: Title: Medical biochemistry; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra medicinske biokemije i laboratorijske medicine (magistar/magistra medicinske biokemije i laboratorijske medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2022-03-15 11:19:46